Brand Intelligence Graph
Company Overview
About Poplar Therapeutics
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Business Model & Competitive Advantage
IgE is the antibody isotype that drives allergic responses: food allergies, asthma, atopic dermatitis, and eosinophilic disorders are all IgE-mediated conditions. Xolair (omalizumab, $3B+ annually) is the only approved anti-IgE antibody, blocking free IgE from binding to mast cells but without reducing total IgE production. Dupixent addresses atopic conditions through a different mechanism. PHB-050's triple mechanism — acting at three points in the IgE pathway simultaneously — may achieve more complete IgE suppression than Xolair, enabling treatment of patients with higher IgE levels that Xolair cannot adequately control.
Competitive Landscape 2025–2026
The $95 million in 60 days without clinical data is a strong signal of institutional conviction in the preclinical pharmacology: SR One, Vida, and RA Capital are among the most scientifically rigorous biotech investors who require compelling preclinical data before committing capital at this scale.
Key Differentiators
Emerging Innovator
Poplar Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Poplar Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Poplar Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Poplar Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Poplar Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →